These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
317 related articles for article (PubMed ID: 27322586)
1. A Comparative Study of Noninvasive Hypoxia Imaging with 18F-Fluoroerythronitroimidazole and 18F-Fluoromisonidazole PET/CT in Patients with Lung Cancer. Wei Y; Zhao W; Huang Y; Yu Q; Zhu S; Wang S; Zhao S; Hu X; Yu J; Yuan S PLoS One; 2016; 11(6):e0157606. PubMed ID: 27322586 [TBL] [Abstract][Full Text] [Related]
2. Comparison of 18F-Fluoroerythronitroimidazole and 18F-fluorodeoxyglucose positron emission tomography and prognostic value in locally advanced non-small-cell lung cancer. Li L; Hu M; Zhu H; Zhao W; Yang G; Yu J Clin Lung Cancer; 2010 Sep; 11(5):335-40. PubMed ID: 20837459 [TBL] [Abstract][Full Text] [Related]
3. Measuring tumor hypoxia with ¹⁸F-FETNIM PET in esophageal squamous cell carcinoma: a pilot clinical study. Yue J; Yang Y; Cabrera AR; Sun X; Zhao S; Xie P; Zheng J; Ma L; Fu Z; Yu J Dis Esophagus; 2012 Jan; 25(1):54-61. PubMed ID: 21595781 [TBL] [Abstract][Full Text] [Related]
4. ¹⁸F-HX4 hypoxia imaging with PET/CT in head and neck cancer: a comparison with ¹⁸F-FMISO. Chen L; Zhang Z; Kolb HC; Walsh JC; Zhang J; Guan Y Nucl Med Commun; 2012 Oct; 33(10):1096-102. PubMed ID: 22836736 [TBL] [Abstract][Full Text] [Related]
5. Comparison of Hypermetabolic and Hypoxic Volumes Delineated on [ Thureau S; Modzelewski R; Bohn P; Hapdey S; Gouel P; Dubray B; Vera P Mol Imaging Biol; 2020 Jun; 22(3):764-771. PubMed ID: 31432388 [TBL] [Abstract][Full Text] [Related]
6. Comparison of the biodistribution of two hypoxia markers [18F]FETNIM and [18F]FMISO in an experimental mammary carcinoma. Grönroos T; Bentzen L; Marjamäki P; Murata R; Horsman MR; Keiding S; Eskola O; Haaparanta M; Minn H; Solin O Eur J Nucl Med Mol Imaging; 2004 Apr; 31(4):513-20. PubMed ID: 14722675 [TBL] [Abstract][Full Text] [Related]
7. [Value of 18F-FETNIM PET-CT for detection of tumor hypoxia in non-small-cell lung cancer]. Hu M; Kong L; Zhao SQ; Yang GR; Yang WF; Han AQ; Fu Z; Ma L; Zheng JS; Yu JM Zhonghua Zhong Liu Za Zhi; 2010 Jun; 32(6):463-6. PubMed ID: 20819492 [TBL] [Abstract][Full Text] [Related]
8. To Explore a Representative Hypoxic Parameter to Predict the Treatment Response and Prognosis Obtained by [ Li L; Wei Y; Huang Y; Yu Q; Liu W; Zhao S; Zheng J; Lu H; Yu J; Yuan S Mol Imaging Biol; 2018 Dec; 20(6):1061-1067. PubMed ID: 29623510 [TBL] [Abstract][Full Text] [Related]
9. Prognostic impact of hypoxia imaging with 18F-misonidazole PET in non-small cell lung cancer and head and neck cancer before radiotherapy. Eschmann SM; Paulsen F; Reimold M; Dittmann H; Welz S; Reischl G; Machulla HJ; Bares R J Nucl Med; 2005 Feb; 46(2):253-60. PubMed ID: 15695784 [TBL] [Abstract][Full Text] [Related]
10. Tumor Hypoxia Response After Targeted Therapy in EGFR-Mutant Non-Small Cell Lung Cancer: Proof of Concept for FMISO-PET. Arvold ND; Heidari P; Kunawudhi A; Sequist LV; Mahmood U Technol Cancer Res Treat; 2016 Apr; 15(2):234-42. PubMed ID: 25759424 [TBL] [Abstract][Full Text] [Related]
11. Hypoxia imaging with 18F-fluoroerythronitroimidazole integrated PET/CT and immunohistochemical studies in non-small cell lung cancer. Hu M; Xing L; Mu D; Yang W; Yang G; Kong L; Yu J Clin Nucl Med; 2013 Aug; 38(8):591-6. PubMed ID: 23797219 [TBL] [Abstract][Full Text] [Related]
12. High reproducibility of tumor hypoxia evaluated by 18F-fluoromisonidazole PET for head and neck cancer. Okamoto S; Shiga T; Yasuda K; Ito YM; Magota K; Kasai K; Kuge Y; Shirato H; Tamaki N J Nucl Med; 2013 Feb; 54(2):201-7. PubMed ID: 23321456 [TBL] [Abstract][Full Text] [Related]
13. Interobserver agreement of qualitative analysis and tumor delineation of 18F-fluoromisonidazole and 3'-deoxy-3'-18F-fluorothymidine PET images in lung cancer. Thureau S; Chaumet-Riffaud P; Modzelewski R; Fernandez P; Tessonnier L; Vervueren L; Cachin F; Berriolo-Riedinger A; Olivier P; Kolesnikov-Gauthier H; Blagosklonov O; Bridji B; Devillers A; Collombier L; Courbon F; Gremillet E; Houzard C; Caignon JM; Roux J; Aide N; Brenot-Rossi I; Doyeux K; Dubray B; Vera P J Nucl Med; 2013 Sep; 54(9):1543-50. PubMed ID: 23918733 [TBL] [Abstract][Full Text] [Related]
14. Introducing fluorine-18 fluoromisonidazole positron emission tomography for the localisation and quantification of pig liver hypoxia. Piert M; Machulla H; Becker G; Stahlschmidt A; Patt M; Aldinger P; Dissmann PD; Fischer H; Bares R; Becker HD; Lauchart W Eur J Nucl Med; 1999 Feb; 26(2):95-109. PubMed ID: 9933343 [TBL] [Abstract][Full Text] [Related]
15. Imaging of blood flow and hypoxia in head and neck cancer: initial evaluation with [(15)O]H(2)O and [(18)F]fluoroerythronitroimidazole PET. Lehtiö K; Oikonen V; Grönroos T; Eskola O; Kalliokoski K; Bergman J; Solin O; Grénman R; Nuutila P; Minn H J Nucl Med; 2001 Nov; 42(11):1643-52. PubMed ID: 11696633 [TBL] [Abstract][Full Text] [Related]
17. Radiosensitizing effect of irisquinone on glioma through the downregulation of HIF-1α evaluated by 18F-FDG and 18F-FMISO PET/CT. Wang H; Zhang Y; Yu W; Zhao X; Xue Y; Xu H Nucl Med Commun; 2016 Jul; 37(7):705-14. PubMed ID: 26963468 [TBL] [Abstract][Full Text] [Related]
18. [18F]EF3 is not superior to [18F]FMISO for PET-based hypoxia evaluation as measured in a rat rhabdomyosarcoma tumour model. Dubois L; Landuyt W; Cloetens L; Bol A; Bormans G; Haustermans K; Labar D; Nuyts J; Grégoire V; Mortelmans L Eur J Nucl Med Mol Imaging; 2009 Feb; 36(2):209-18. PubMed ID: 18690432 [TBL] [Abstract][Full Text] [Related]
19. Yu W; Qiao F; Su X; Zhang D; Wang H; Jiang J; Xu H Biomed Pharmacother; 2019 Nov; 119():109454. PubMed ID: 31526971 [TBL] [Abstract][Full Text] [Related]
20. Development of F-18-labeled fluoroerythronitroimidazole as a PET agent for imaging tumor hypoxia. Yang DJ; Wallace S; Cherif A; Li C; Gretzer MB; Kim EE; Podoloff DA Radiology; 1995 Mar; 194(3):795-800. PubMed ID: 7862981 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]